OCUP - Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
- Ocuphire Pharma ( NASDAQ: OCUP ) said on Thursday the last patient of the 103 enrolled subjects had completed their 24-week study visit in the Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy.
- The company said top-line results from the trial are expected in Q4.
- APX3330 is a potential oral treatment for diabetic retinopathy/diabetic macular edema.
- Interim safety results showed favorable safety and tolerability profile, consistent with 11 prior trials of APX3330.
- ( OCUP ) rose 1.5% .
For further details see:
Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment